EVAX Evaxion A/S IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1828253 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY125.1%
TTM net income YoY27.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-122.7%
Net margin-102.4%
FCF margin-88.2%
EBITDA margin—
Returns
ROE-100.2%
ROA-37.7%
ROIC (approx.)—
Asset turnover0.37x
Leverage & solvency
Liabilities / assets40.0%
Debt / equity0.32x
Current ratio5.85x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $7.53M | $3.34M | $73,000 | $0 | — |
| R&D expense | $9.97M | $10.46M | $11.92M | $17.06M | $19.58M |
| SG&A expense | $6.79M | $7.62M | $10.35M | $8.21M | $6.25M |
| Operating income | -$9.23M | -$14.73M | -$22.20M | -$25.26M | -$25.83M |
| Interest expense | $0 | $0 | $1,000 | $34,000 | $5,000 |
| Pretax income | -$8.62M | -$11.36M | -$22.91M | -$23.94M | -$24.71M |
| Income tax | -$908,000 | -$788,000 | -$790,000 | -$772,000 | -$178,000 |
| Net income | -$7.71M | -$10.57M | -$22.12M | -$23.17M | -$24.53M |
| EPS (basic) | -0.02 | -0.20 | -0.81 | -0.98 | -1.26 |
| EPS (diluted) | — | — | -0.81 | -0.98 | -1.26 |
| Balance sheet | |||||
| Cash & equivalents | $23.23M | $5.95M | $5.58M | $13.18M | $32.17M |
| Receivables | — | — | $1.95M | $2.79M | $1.14M |
| Current assets | $24.90M | $8.77M | $8.35M | $16.98M | $34.70M |
| PP&E, netmay include right-of-use assets (IFRS) | $3.32M | $3.51M | $4.34M | $4.67M | $5.17M |
| Intangibles | $0 | $0 | $0 | — | $93,000 |
| Total assets | $28.41M | $12.48M | $12.89M | $22.02M | $40.16M |
| Current liabilities | $4.26M | $4.37M | $7.08M | $3.76M | $4.32M |
| Short-term debt | $190,000 | $159,000 | $159,000 | $136,000 | $126,000 |
| Long-term debt | $5.35M | $8.01M | $8.49M | $7.86M | $1.04M |
| Total debt | $5.54M | $8.17M | $8.65M | $8.00M | $1.17M |
| Total liabilities | $11.37M | $14.14M | $17.62M | $13.72M | $7.73M |
| Shareholders' equity | $17.04M | -$1.65M | -$4.73M | $8.30M | $32.44M |
| Net debt | -$17.70M | $2.21M | $3.06M | -$5.18M | -$31.00M |
| Shares outstanding | 417.01M | — | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$6.62M | -$12.94M | -$17.69M | -$25.77M | -$21.93M |
| Capital expenditure | $11,000 | $0 | $87,000 | $292,000 | $1.30M |
| Free cash flow | -$6.64M | -$12.94M | -$17.78M | -$26.07M | -$23.23M |
| Investing cash flow | -$14,000 | -$3,000 | -$93,000 | -$268,000 | -$1.33M |
| Financing cash flow | $22.41M | $13.13M | $10.69M | $7.85M | $49.80M |
| Stock-based compensation | $307,000 | $357,000 | $479,000 | $942,000 | $1.38M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.